摘要
1同类药物的比较（特别是作用机理相同的药物）
资料来源：采用卫生技术评估（HTA）方法，全面检索MEDLINE、PubMed、CHKD，FDA网站选取药物安全性及有效性的文章。
出处
《药品评价》
CAS
2011年第18期16-17,共2页
Drug Evaluation
同被引文献12
-
1Yang W,Lu J,Weng J. Prevalence of diabetes among men and women in China[J].New England Journal of Medicine,2010.1090-1101.doi:10.1056/NEJMoa0908292.
-
2Nielsen LL,Young AA,Parkes DG. Pharmacology of exenatide (synthetic exendin-4):a potential therapeutic for improved glycemic control of type 2 diabetes[J].Regulatory Peptides,2004.77-88.doi:10.1016/j.regpep.2003.10.028.
-
3Vilsboll T. Liraglutide a once-daily GLP-1 analogue for the treatment of type 2 diabetes mellitus[J].Expert Opinion on Investigational Drugs,2007.231-237.
-
4Deacon CF,Nauck MA,Toft-Nielsen M. Both subcutaneously and intravenously administered glucagon-like peptide 1 are rapidly degraded from the NH2-terminus in type Ⅱ diabetic patients and in healthy subjects[J].Diabetes,1995.1126-1131.
-
5Lovshin JA,Drucker DJ. Incretin based therapies for type 2 diabetes mellitus[J].Nat Rev Endocrinol,2009.262-269.doi:10.1038/nrendo.2009.48.
-
6Davidson J. Advances in therapy for type 2 diabetes:GLP-1 receptor agonists and DPP 4 inhibitors[J].Cleveland Clinic Journal of Medicine,2009,(Suppl 5):S28-S38.
-
7Buse JB,Rosenstock J,Sesti G. Liraglutide once a day versus exenatide twice a day for type 2 diabetes;a 26-week randomised,parallel-group,multinational,open-label trial (LEAD-6)[J].The Lancet,2009.39-47.
-
8Buse JB,Sesti G,Schmidt WE. Switching to once-daily liraglutide from twice-daily exenatide further improves glycemic control in patients with type 2 diabetes using oral agents[J].Diabetes Care,2010.1300-1303.
-
9Buse JB,Garber A,Rosenstock J. Liraglutide treatment is associated with a low frequency and magnitude of antibody formation with no apparent impact on glycemic response or increased frequency of adverse events:results from the Liraglutide Effect and Action in Diabetes (LEAD) trials[J].Journal of Clinical Endocrinology and Metabolism,2011.1695-1702.
-
10Pratley RE,Nauck M,Bailey T. Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin.a 26-week,randomised,parallel group,open-label trial[J].The Lancet,2010.1447-1456.
二级引证文献2
-
1佘德军,李伟,丁煜,于希忠.抑火理脾颗粒剂对2型糖尿病患者血清胰高血糖素样肽-1水平的影响[J].河南中医,2016,36(12):2190-2192.
-
2范玲,谢星星,范小冬,熊玉霞.利司鲁肽治疗2型糖尿病的系统评价[J].中国医院药学杂志,2017,37(3):254-257. 被引量：5
-
1常明.第五章 药品顺应性评价指南[J].药品评价,2011,8(18):13-14.
-
2秦瑀.瑞典卫生技术评估摘要(SBU Alert)(6)[J].中国循证医学,2002,2(2):140-141. 被引量：1
-
3金有豫.第八章 药品信息服务评价指南[J].药品评价,2011,8(18):17-19.
-
4汪桂清.英国制药企业上市后药物安全性评价指南[J].药物流行病学杂志,1995,4(2):117-120. 被引量：1
-
5门鹏,顾歆纯,翟所迪.维格列汀治疗2型糖尿病的卫生技术评估[J].药物流行病学杂志,2016,25(9):533-540. 被引量：4
-
6徐小薇.中国药品综合评价指南参考大纲(第二版) 第一章 药品安全性评价指南[J].药品评价,2015,12(8):15-16. 被引量：7
-
7美国FDA称罗氏血糖仪可能致命[J].糖尿病天地（文摘刊）,2010(5):8-8.
-
8梅丹.第四章 药品质量评价指南[J].药品评价,2011,8(18):11-13.
-
9门鹏,唐惠林,翟所迪.沙格列汀治疗2型糖尿病的有效性、安全性和经济性的快速卫生技术评估[J].中国新药杂志,2015,24(23):2751-2755. 被引量：6
-
10王琪（摘）.08088 对Tequin的警告进一步升级[J].国外药讯,2006(8):40-40.
